GlassScriptPhysician profile
Wisam Daoud
NPI 1083238562
$2,496.40
in general payments reported to CMS, 2019-2025
19 companies · $1,760 in 2025
The $1,760 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $101 · 2024: $635 · 2025: $1,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,496.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $462.62 | 2024-2025 | Azure Xt Dr Mri Surescan, Linq II, Cobalt Dr Mri Surescan |
| Penumbra, INC. | $377.09 | 2024-2025 | Indigo System |
| Abbott Laboratories | $257.56 | 2025 | Coroflow, Gallant, Aveir |
| Boston Scientific Corporation | $230.39 | 2024-2025 | Watchman Flx, General - Crm_crm, General - Therapies |
| Shockwave Medical, INC | $176.45 | 2024-2025 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Stryker Corporation | $157.00 | 2025 | Flowtriever |
| Abbvie INC. | $143.45 | 2023-2025 | Teflaro, Dalvance, Avycaz |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $141.07 | 2024-2025 | Lifevest |
| Abiomed | $104.95 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $101.76 | 2024-2025 | |
| Pfizer INC. | $94.70 | 2023-2025 | |
| Cardiva Medical, INC. | $78.82 | 2025 | Optowire, Cardiva Vascade 6/7f Vcs |
| Kiniksa Pharmaceuticals International, Plc | $50.96 | 2024 | Arcalyst |
| Recor Medical INC | $25.48 | 2025 | Paradise Ultrasound Renal Denervation System |
| Impulse Dynamics (USA) INC. | $19.73 | 2025 | Optimizer |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $19.47 | 2025 | Guideliner |
| Scpharmaceuticals INC. | $19.40 | 2025 | |
| Asahi Intecc USA, INC. | $18.43 | 2024 | Peripheral Vascular |
| Terumo Medical Corporation | $17.07 | 2024 | Angio-Seal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wisam Daoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.